CIN and HR-HPV Treatment Market Report – Size & Outlook 2028

CIN & HR-HPV Treatment Market Forecast to 2028 - Global Analysis By Disease Type (Cervical Intraepithelial Neoplasia 1, Cervical Intraepithelial Neoplasia 2, and Cervical Intraepithelial Neoplasia 3), Strain Type (HPV 16, HPV 18, and Others), Offering (Diagnostic Method and Treatment), Product Type (Kits & Reagents, Instruments, and Services), and End User (Hospitals & Clinics, Diagnostic Laboratories, Specialized Clinical Laboratories, and Others)

Publication Month : May 2023

  • Report Code : TIPRE00029878
  • Category : Pharmaceuticals
  • Status : Published
  • No. of Pages : 245
Inquire Before Buy



[Research Report] The CIN & HR-HPV treatment market size is expected to reach US$ 17,164.61 million by 2028 from US$ 11,635.17 million in 2022; the market is estimated to record a CAGR of 6.7% from 2023 to 2028.

The CIN & HR-HPV treatment market is segmented on the basis of disease type, strain type, offerings, product type, end user, and geography. The report offers insights and in-depth analysis of the market, emphasizing parameters such as drivers, trends, and opportunities in the market and competitive landscape analysis of leading market players across various regions. It also includes analyses of the impact of the COVID-19 pandemic across major regions.

Market Insights

Favorable Initiatives for Preventing Cervical Cancer Drives CIN & HR-HPV Treatment Market Growth

In August 2020, the World Health Organization (WHO) devised a global strategy for the elimination of cervical cancer. Per this strategy, all countries in the world must focus on reaching and maintaining an incidence rate of less than 4 per 100,000 women to eliminate cervical cancer. To attain such low incidence rates, countries should focus on cervical cancer screening, treatment, and vaccination. Medicare, a popular government insurance program, provides coverage for PAP tests, pelvic exams, and clinical breast examinations performed every two years for cervical cancer screening.

Unitaid, a global health agency that works to bring about innovative solutions to prevent, diagnose, and treat major diseases in low- and middle-income countries, has come up with a new initiative for cervical cancer prevention. Its efforts are focused on expanding access to critical tools and services to screen for the early signs of cervical cancer, followed by the treatment of positive cases. Unitaid is providing support for the Clinton Health Access Initiative (CHAI) and the Scale Up Cervical Cancer Elimination with Secondary Prevention Strategy (SUCCESS) Project, which are being carried out in partnership with Expertise France, Jhpiego, and the Union for International Cancer Control (UICC). Unitaid is collaborating with these partners and governments of 14 low- and middle-income countries to develop an affordable and highly effective package of tools, which can help the World Health Organization achieve its cervical cancer elimination targets. The Unitaid has invested ~US$ 70 million in innovative tools to screen women living in low-resource environments for precancer conditions and treat them. In 14 countries, Unitaid is striving to overcome access barriers and laying the groundwork for national cervical cancer elimination efforts, demonstrating effective models of prevention across low- and middle-income countries.

Customize Research To Suit Your Requirement

We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.

CIN & HR-HPV Treatment Market: Strategic Insights

Market Size Value inUS$ 11,635.17 million in 2022
Market Size Value byUS$ 17,164.61 million by 2028
Growth rateCAGR of 6.7% from 2023 to 2028
Forecast Period2023-2028
Base Year2022
Analyst Image


Have a question?

Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

Analyst Image  Speak to Analyst

In India, screening methods such as cytology, co-testing (HPV + cytology), primary HPV testing, and visual inspection with acetic acid are employed in various settings, according to resource availability and compliance standards. The Federation of Obstetricians and Gynaecologists of India (FOGSI) has published good clinical practice recommendations (GCPR) for the management of screen-positive women in different resource settings. RMNCH + A (which stands for Reproductive Maternal Neonatal Childhood Health + Adolescent Health + Adolescent) is the strategy of the National Health Mission of India (NHM) that encourages small family norms. This strategy involves delivering contraceptives at home by Accredited Social Health Activists (ASHA), delaying marriage age, promoting menstrual hygiene and sexual hygiene awareness, and prompting the treatment of reproductive tract illnesses in "Suraksha Clinics."

Such initiatives by various healthcare organizations and governments for preventing cervical cancer boost the growth of the CIN & HR-HPV treatment market.

Disease Type-Based Insights

Based on disease type, the CIN & HR-HPV treatment market is segmented into cervical intraepithelial neoplasia 1 (CIN 1), cervical intraepithelial neoplasia 2 (CIN 2), and cervical intraepithelial neoplasia 3 (CIN 3). In 2022, the cervical intraepithelial neoplasia 3 (CIN 3) segment held the largest market share, and it is anticipated to register the highest CAGR during the forecast period.

CIN & HR-HPV Treatment Market, by Disease Type – 2022–2028

  • Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
  • Request discounts available for Start-Ups & Universities
Strain Type-Based Insights

Based on strain type, the CIN & HR-HPV treatment market is segmented into HPV 16, HPV 18, and others. The HPV 16 segment held the largest share of the market in 2022. Th HPV 18 segment is expected to record the highest CAGR during the forecast period.

Offering-Based Insights

Based on offering, the CIN & HR-HPV treatment market is categorized into diagnostic method and treatment. In 2022, the treatment segment held a larger share of the market. However, diagnostic method segment is expected to register a higher CAGR during the forecast period. Further, the diagnostic method segment is further categorized into HPV testing, Pap smear test, colposcopy, and biopsy. The HPV testing segment held the largest share on the market for diagnostic method in 2022. In addition, the treatment segment is bifurcated into excisional surgery and ablative techniques. In 2022, the ablative techniques segment held a larger share of the market and is anticipated to register a higher CAGR in the market during the forecast period.

Product Type-Based Insights

Based on product type, the CIN & HR-HPV treatment market is segmented into kits & reagents, instruments, and services. The services segment held the largest share of the market in 2022, and it is expected to record the highest CAGR during the forecast period.

End User-Based Insights

Based on end user, the CIN & HR-HPV treatment market is segmented into hospitals & clinics, diagnostic laboratories, specialized clinical laboratories, and others. The hospital & clinics segment accounted for the largest market share in 2022. The diagnostic laboratories segment is expected to record the highest CAGR during the forecast period.

The CIN & HR-HPV treatment market players adopt organic strategies such as product launch and expansion to expand their geographic footprint and product portfolios. Additionally, these growth strategies help companies strengthen their clientele and enlarge their product portfolios.

  • In October 2022, Fujirebio Europe and Self-screen BV formed a commercial collaboration to distribute the PreCursor-M+ methylation-specific molecular in-vitro diagnosis (IVD) assay (a trademark of Self-screen BV). The test is intended for qualitatively detecting the elevated methylation levels of cervical cancer biomarkers. It may be used as a triage follow-up test on women with HPV-positive results and ASCUS/LSIL cytology. The PreCursor-M+ assay completes Fujirebio's HPV-specific molecular test portfolio.
  • In April 2021, Roche received US FDA approval for the fully automated, high throughput cobas 6800/8800 Systems for their use in HPV testing. The cobas HPV test identifies women at risk of cervical cancer by detecting the presence of hrHPV DNA in cervical samples. cobas HPV is indicated for routine cervical cancer screening per professional medical guidelines, including triage of ASC-US cytology and primary HPV screening of women to assess the risk for cervical precancer and cancer.

Company Profiles

  • Fujirebio Europe NV                    
  • Qiagen NV                                
  • Zilico Ltd                                  
  • Abbott Laboratories                    
  • Cepheid                                   
  • F. Hoffmann-La Roche Ltd            
  • INOVIO Pharmaceuticals Inc
  • Bioneer Corp                             
  • Antiva Biosciences Inc                 
  • Thermo Fisher Scientific Inc.
Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

Disease Type, Strain Type, Offering, Product Type, and End User

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

Argentina, Australia, Brazil, Canada, China, France, Germany, India, Italy, Japan, Mexico, Saudi Arabia, South Africa, South Korea, Spain, United Arab Emirates, United Kingdom, United States

Frequently Asked Questions

Which region is expected to witness significant demand for CIN and HR-HPV Treatment Market in the coming years?

Global CIN and HR-HPV Treatment Market is segmented by region into North America, Europe, Asia Pacific, Middle East & Africa and South & Central America. North America held the largest market share of the CIN and HR-HPV Treatment Market in 2021. With several North American market players focusing on research and development activities, the regional market for CIN and HR-HPV Treatment Market is likely to propel in North America region during the forecast period.

Which are the top companies that hold the market share in CIN & HR-HPV Treatment Market?

Abbott and Cepheid are the top two companies that hold huge market shares in the CIN & HR-HPV Treatment Market.

Who are the key players in the CIN & HR-HPV Treatment Market?

The CIN and HR-HPV Treatment Market majorly consists of the players such Fujirebio Europe NV, Qiagen NV, Zilico Ltd, Abbott Laboratories, Cepheid, F. Hoffmann-La Roche Ltd, INOVIO Pharmaceuticals Inc, Bioneer Corp, Antiva Biosciences Inc, and Thermo Fisher Scientific Inc.

Which end user held the largest share in the CIN & HR-HPV Treatment Market?

The hospitals & clinics segment dominated the global CIN and HR-HPV Treatment Market and held the largest market share in 2021.

What is the market CAGR value of CIN and HR-HPV Treatment Market during forecast period?

The CAGR value of the CIN and HR-HPV Treatment Market during the forecasted period of 2022-2028 is 6.7%.

Which disease type leads the CIN & HR-HPV Treatment Market ?

Cervical Intraepithelial Neoplasia 3 segment held the largest share of the market in the global CIN and HR-HPV Treatment Market and held the largest market share of 47.48% in 2022.

What are CIN & HR-HPV?

High-risk HPV is associated with cervical intraepithelial neoplasia (CIN). Persistent infection with high-risk human papillomavirus (HPV) results in invasive cervical cancer. Also, HR-HPV subtypes particularly HPV 16 and HPV 18 causes cervical cancer. The main aim of NHS Cervical Screening Program (NHS CSP) is to reduce the incidence and mortality from cervical cancer through a systematic, quality-assured population-based screening program for people aged 24 to 64.

What are the driving factors for the CIN and HR-HPV Treatment Market across the globe?

Key factors that are driving the growth of this market are Increase in prevalence of human papillomavirus infections and favorable Initiatives for preventing cervical cancer.

The List of Companies - CIN & HR-HPV Treatment Market

  1. Fujirebio Europe NV
  2. Qiagen NV 
  3. Zilico Ltd  
  4. Abbott Laboratories  
  5. Cepheid
  6. F. Hoffmann-La Roche Ltd  
  7. INOVIO Pharmaceuticals Inc
  8. Bioneer Corp  
  9. Antiva Biosciences Inc  
  10. Thermo Fisher Scientific Inc.

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • 3.1 Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • 3.2 Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • 3.3 Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • 3.4 Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Related Reports